Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cofactors and Coenzymes01:27

Cofactors and Coenzymes

87.0K
Enzymes require additional components for proper function. There are two such classes of molecules: cofactors and coenzymes. Cofactors are metallic ions and coenzymes are non-protein organic molecules. Both of these types of helper molecule can be tightly bound to the enzyme or bound only when the substrate binds.
87.0K
Cofactors and Coenzymes01:24

Cofactors and Coenzymes

12.6K
Enzymes are proteins made of amino acids. The functional group of each constituent amino acid catalyzes a wide variety of chemical reactions via ionic interactions or acid-base reactions. However, amino acids cannot catalyze oxidation-reduction and group transfer reactions and need to be aided by non-protein components called cofactors. Cofactors are also referred to as the chemical teeth of an enzyme.
Cofactors can be metallic ions or organic molecules called coenzymes. These types of helper...
12.6K
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of 24-Hour Blood Pressure Variability With Cognition and Brain MRI Markers of Structural Change in Adults in Mid- to Late-Life.

Neurology·2026
Same author

Twenty-four-hour blood pressure and CSF biomarkers of Alzheimer's disease and related dementias in a community cohort.

GeroScience·2026
Same author

Wellbeing and quality of life secondary outcomes from a Mediterranean Diet and walking randomised controlled trial in older Australians.

Public health nutrition·2026
Same author

Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia.

Neurology·2026
Same author

Association of an Aquaporin-4 Haplotype With Cognition, Brain Volume, and Dementia Risk in Community-Dwelling Individuals Without Dementia.

Neurology·2026
Same author

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy.

Annals of clinical and translational neurology·2026
Same journal

Correction: Pramesthi et al. Evaluating the Impact of Indonesia's National School Feeding Program (ProGAS) on Children's Nutrition and Learning Environment: A Mixed-Methods Approach. <i>Nutrients</i> 2025, <i>17</i>, 3575.

Nutrients·2026
Same journal

Correction: Huang et al. Correlation Study Between Dietary Behaviors, Lifestyle, and Psychological Problems in Chinese Children Aged 3-7. <i>Nutrients</i> 2025, <i>17</i>, 176.

Nutrients·2026
Same journal

Association of Dietary Animal and Plant Protein Composition with All-Cause Mortality: 24-Year Population-Based Cohort Study.

Nutrients·2026
Same journal

Phytochemistry, Bioavailability, and Molecular Mechanisms Underlying Multitarget Anticancer Activity of <i>Aloe vera</i>.

Nutrients·2026
Same journal

A Comparison of the Interstitial and Blood Glucose Responses Following Consumption of Different Carbohydrate-Containing Beverages in Humans: A Randomised Controlled Trial.

Nutrients·2026
Same journal

Across Kingdoms: The Bacteriome, Mycobiome, and Virome in Autoimmune Diseases: Mechanistic Insights, Therapeutic Perspectives, and the Emerging Role of COVID-19.

Nutrients·2026
See all related articles

Related Experiment Video

Updated: Jan 18, 2026

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

11.1K

Coenzyme Q10 and Cognition: A Review.

Madeleine C Nankivell1, Franklin Rosenfeldt1,2, Andrew Pipingas1

  • 1Centre for Mental Health and Brain Sciences, Swinburne University, Melbourne, VIC 3122, Australia.

Nutrients
|September 13, 2025
PubMed
Summary
This summary is machine-generated.

Coenzyme Q10 (CoQ10) shows potential for improving cognitive function in older adults by addressing age-related decline. However, research results are mixed, necessitating further investigation into its efficacy and mechanisms.

Keywords:
CoQ10Coenzyme Q10ageingcognition

More Related Videos

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.6K
Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

2.2K

Related Experiment Videos

Last Updated: Jan 18, 2026

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

11.1K
Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

2.6K
Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

2.2K

Area of Science:

  • Gerontology
  • Neuroscience
  • Biochemistry

Background:

  • Cognitive decline is a growing concern in aging Western populations.
  • Age-related changes like inflammation, oxidative stress, and reduced cerebral blood flow contribute to cognitive decline.
  • Coenzyme Q10 (CoQ10), an antioxidant, is being explored for its potential to mitigate these changes.

Purpose of the Study:

  • To review the efficacy of Coenzyme Q10 (CoQ10) supplementation on cognitive function in the elderly.
  • To explore the impact of CoQ10 on biological mechanisms underlying cognitive decline.

Main Methods:

  • A review of animal studies and human clinical trials was conducted.
  • Studies investigated CoQ10's effects on cognition in healthy individuals and those with specific diseases.
  • Data from twelve studies showing cognitive improvement and two showing reduced oxidative stress were analyzed.

Main Results:

  • Four out of eight human clinical trials indicated a beneficial effect of CoQ10 on cognition.
  • Two trials showed increased cerebral blood flow with CoQ10 supplementation.
  • Some studies demonstrated improved cognitive function and reduced oxidative stress with CoQ10.

Conclusions:

  • Coenzyme Q10 (CoQ10) therapy may positively impact cognition and its regulatory mechanisms.
  • The current literature presents mixed results, with some human trials reporting no cognitive benefits.
  • Further research with targeted mechanisms and diverse cognitive assessments is needed to fully evaluate CoQ10's role in aging and neurodegenerative diseases.